CV Sciences (CVSI) Operating Income Growth (3y) (2015 - 2026)
CV Sciences (CVSI) Operating Income Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 40.17% |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | -27.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.14% |
| Dec 31, 2025 | 67.20% |
| Sep 30, 2025 | 32.45% |
| Jun 30, 2025 | 61.61% |
| Mar 31, 2025 | 26.14% |
| Dec 31, 2024 | 58.20% |
| Sep 30, 2024 | 51.45% |
| Jun 30, 2024 | 45.03% |
| Mar 31, 2024 | 41.60% |
| Dec 31, 2023 | 54.54% |
| Sep 30, 2023 | 48.24% |
| Jun 30, 2023 | 38.64% |
| Mar 31, 2023 | 45.54% |
| Dec 31, 2022 | 33.86% |
| Sep 30, 2022 | 20.47% |
| Jun 30, 2022 | -56.68% |
| Mar 31, 2022 | 45.54% |
| Dec 31, 2021 | -73.33% |
| Sep 30, 2021 | -41.70% |
| Jun 30, 2021 | -45.25% |